Shannon Thyme Klinger - Feb 28, 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Chief Legal Officer
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol: MRNA
Transactions as of: Feb 28, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/2/2023, 05:09 PM
Previous filing: Dec 9, 2022
Next filing: Mar 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MRNA	Common Stock						4.77K	Feb 28, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Stock Option (Right to Buy)	Award	$0	+20K		$0.00	20K	Feb 28, 2023	Common Stock	20K	$138.81	Direct	F1
transaction	MRNA	Restricted Stock Units	Award	$0	+5.26K		$0.00	5.26K	Feb 28, 2023	Common Stock	5.26K	$0.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of this option will vest and become exercisable on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F2	25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.